Skip to content

Study · Not a test of the peptide alone · 2025

1 result

[Down-regulation of ACADM-mediated lipotoxicity inhibits invasion and metastasis of estrogen receptor-positive breast cancer cells].

Li J, Xian R, Li R

Nan fang yi ke da xue xue bao = Journal of Southern Medical University1 Jun 2025

PMID40579130 (opens in a new tab)PMCIDPMC12204834 (opens in a new tab)DOI10.12122/j.issn.1673-4254.2025.06.06 (opens in a new tab)PepBankPUB-40579130
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    In ACADM-knockdown MCF-7 and T47D breast cancer cells, treatment with a ROS scavenger, elamipretide or SC79 reversed the reduced invasive capacity.

    In plain wordsIn cells, three treatments, including elamipretide, restored the lower invasion seen after ACADM knockdown. This tested the ACADM pathway.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseInvasive capacity of ACADM-knockdown cells
    Study

    humann: not reported in source

    MCF-7 and T47D breast cancer cells with ACADM knockdown
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    ACADM knockdown significantly decreased the invasive capacity of the cells, which were obviously reversed by treatment with ROS scavenger, Elamipretide, and SC79.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.